Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 131

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 131
---
 competition for qualified
personnel in the medical innovation industry is intense, and we may incur significant costs to attract and retain them. We will need to
hire additional personnel as we continue to expand our development activities and drive sales of our products or product candidates. We
may not attract, retain and develop quality personnel on acceptable terms due to the competition for such personnel. If we are not able
to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly
impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business
strategy.

The acquisitions of the
Targets by Longevity are conditioned, in part, on the satisfaction or waiver of certain closing conditions. If such closing conditions
are waived pursuant to the agreements governing such acquisitions, Longevity’s business would be materially harmed.

As discussed
elsewhere in this proxy statement/prospectus, Longevity has entered into Contribution and Exchange Agreements (as amended, the “C&E
Agreements”) with each of the Targets and their respective stockholders or members. Pursuant to the C&E Agreements, the consummation
of each acquisition (collectively, the “Target Acquisitions”) is conditioned upon the satisfaction or waiver of certain closing
conditions including amongst other items, (i) the closing of each of the other Target Acquisitions and (ii) the closing of a business
combination with a valuation of not less than $75 million. The foregoing conditions may be waived on behalf of each of each Target by
the representative of their respective stockholders or members as detailed in the C&E Agreements. In the event that the foregoing
conditions are waived on behalf of one or more of the Targets, Longevity may be obligated to consummate one or more of the Target Acquisitions
even though one or more of the Target Acquisitions will not be consummated. Further, notwithstanding the waiver of the foregoing conditions,
it is also possible that none of the Target Acquisitions are consummated. If either of the foregoing scenarios should occur, Longevity
may not realize the benefits of the Target Acquisitions as contemplated by this proxy statement/prospectus, including the projected revenues
and other financial metrics related to the Target Acquisitions, and Longevity’s business would be materially harmed.

If we make acquisitions,
we could incur significant costs and encounter difficulties that harm our business.

In the ordinary
course of our business, we expect to from time to time evaluate the acquisition of, investment